We would love to hear your thoughts about our site and services, please take our survey here.
Such a shame that this was communicated in the way that it was... Because I'm coming around to this being great news. Full ownership... Addressing the messy 20%...interests aligned.. Other assets thrown in.
Now, imagine if there had just been up front acknowledgement of this, would have read very differently. That said it is indeed very messy, and various conflicts of interest, so cest la vie...
Overall, bottom line... Great development in unison with finance
Ben...you mention 6 months...pretty much when I put first order in at .16/17 in think.
It's kind of frustrating that VAST and BP have made momentous progress in those 6 months..and nothing in the SP to show for it. As in, it was a hell of a lot more of a risky buy, then than for those that will undoubtedly take positions in the next few weeks/months. But anyhow good luck to new and old investors alike. It's a nice time to have a mine.
and have a good weekend all
newtrade...can't argue with that.
it's all about the balance of risk and potential reward. Riskier this week, but if all comes off, should be higher price next week.
Just noticed the advert on banner at top of LSE..will be interesting to see if brings traffic...a hell of a lot of people will see the ad (if not the video!)
Vast Resources CEO Andrew Prelea celebrates the first sale of copper concentrate from Romanian mine Watch Now
Anyways, back to work. GLA.
Sorry wrong board so doubt it'll bring traffic here ha.
Just noticed the advert at top of page..
Vast Resources CEO Andrew Prelea celebrates the first sale of copper concentrate from Romanian mine Watch Now
Will be interesting to see if that brings traffic this afternoon.
I'm scratching my head a bit at the lack of interest in what seems a really good opportunity here (IMO).
I agree Max on the brightside, re chance to top up and bring my average down. I'm already fully committed here though...albeit that I thought Sarah was too (before this morning) lol.
You'll need the extra income Sarah for the Porshe fuel.
Re confidentiality there may not be a specific clause per se in place with the clinical trials team; as the issue of results relates to good clinical practice as well as confidentiality. i.e. it would be unethical to relay any results prior to analysis and scientific scrutiny from the investigative team. Furthermore, very few people will have access to the overall data as it comes in.
Re follow-up period...it would be all well and good if there are good clinical outcomes in the first few days; but no use if 2 weeks later everyone is dead!. I'm not saying that would happen here but my point is that it would be good to know what the follow up period is for the study. I would guess at a month. If anyone digs out a protocol or outline of the study please let us know.
I work in a clinical trials unit btw.
Buying while others are wary - a high risk high reward strategy in some ways. But you have to look at the fundamentals. I started buying VAST in April when there was a hell of a lot more uncertainty about whether
VAST could deliver on BP. Compared to then they have come a long way; into production and sales revenue imminent. So, notwithstanding the share placing to raise income, this feels like a great opportunity to top up to me. Which I have just done. Paying less than 17 strikes me as good value. Time will tell . While the number of shares is monstrous, so is the mine :-) GLA
My recall was that they would then initiate further trials in the UK and elsewhere.. Anyone seen a protocol for the trial in Brazil? 3 arm trial I recall. May be commercially sensitive. .
I agree that the trajectory is a bit unclear for a lot of things going forward...especially ACCUSTEM - what is the business plan for it..I mean they are about to launch a brand new company, but the level of detail of forward plans is slim (please correct me if I'm wrong).
But...iI have full faith in the board to deliver on both companies; which is why I don't complain too much.
To quote ggp board
10% up in first hour.
Good work US posting crew.. It's a bit like a holiday home over the though... I recognised everyone ha. Interesting few days for us all..then looking forward to demerger and watching both companies grow. I was just thinking how exciting it will be to have the news flow of Accustem in its infant days, especially around the validation results.
LBC..if there is a breakout it could come at any time... but very confident. Short, medium, long term there will IMO be many breakouts in TILS and ACCUSTEM. Fingers crossed for all holders that the next one is indeed imminent. Needs to break the 180 resistance, then could fly.
He was a bit vague re fund raising for accustem.. But confirmed no plan to fund raise initially. They will of course need further funding in due course if proceeding to commercialise and raise value post validation of the diagnostic accuracy which would take approx 6 months.
key takeaway for me was the conviction of KS that SP should not fall post merger, given Stemprinter diagnostic avenue is lost in the TILS therapeutics portfolio, and the small matter of Brazil Covid trial recruitment 1st week of Nov (with first results by end December I believe?) . I'm keen to accumulate Accustem shares until validation is cleared as the new company moves forward with commercialisation and realising the potential value of Stem.
Plus
I'm not of the opinion that there will necessarily be a large post de merger drop in TILS share price given the potential newsflow. But the process does generate uncertainty. However I am confident that both Accustem and TILS will be stronger separated. Especially as the BOD have confirmed the split is about commercialisation; which in SP terms should translate to rises.